DB
VKTX icon

Dmitry Balyasny’s Viking Therapeutics VKTX Stock Holding History

Dmitry Balyasny’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,400
Closed -$260K – 3585
2025
Q4 		$260K Sell
7,400
-200,000
-96% -$7.09M ﹤0.01% 2787
2025
Q3 		$5.45M Sell
207,400
-2,163,900
-91% -$64.6M 0.01% 1334
2025
Q2 		$62.8M Sell
2,371,300
-567,500
-19% -$14.9M 0.09% 257
2025
Q1 		$71M Buy
2,938,800
+2,481,400
+543% +$78.4M 0.12% 201
2024
Q4 		$18.4M Buy
457,400
+429,800
+1,557% +$24.5M 0.03% 703
2024
Q3 		$1.75M Sell
27,600
-29,800
-52% -$1.75M ﹤0.01% 1729
2024
Q2 		$3.04M Buy
+57,400
New +$3.76M 0.01% 1381
2024
Q1 		– Sell
-125,000
Closed -$2.33M – 3157
2023
Q4 		$2.33M Sell
125,000
-915,000
-88% -$12M ﹤0.01% 1404
2023
Q3 		$11.5M Buy
+1,040,000
New +$14.9M 0.02% 792

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dmitry Balyasny's VKTX Position: Q2 2026 in Review

Dmitry Balyasny increased its Viking Therapeutics (VKTX) stake by 218% in Q2 2026, buying an estimated $2.57M and bringing the position to 115,906 shares worth $4.52M. The position accounts for 0.01% of the portfolio, ranked #1415.

Dmitry Balyasny first reported a position in VKTX in Q2 2018 and has held it in 20 quarters since. The position peaked at $41.8M in Q4 2023. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Dmitry Balyasny held 115,906 shares of Viking Therapeutics worth $4.52M as of Q2 2026.
  • Dmitry Balyasny bought 79,413 Viking Therapeutics shares in Q2 2026, an estimated $2.57M.
  • Viking Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1415 holding.
  • Dmitry Balyasny first reported a position in Viking Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • Dmitry Balyasny's Viking Therapeutics position peaked at $41.8M in Q4 2023.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.